Drug Trial Radar · NCT04281524
A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line
Last checked: Nov 20, 2026Latest source record: Mar 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Mar 2020
Primary completion
Aug 2021
Study completion Oct 2021
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Feb 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Peripherally Inserted Central Catheters (PICCs) are commonly used in patients with cancer to administer chemotherapy and supportive care medication. However, PICCs and other medical devices that come into contact with blood increase the risk of blood clots (thrombosis) inside the blood vessels. Conventional blood thinners (anticoagulants) may reduce the risk of thrombosis but they also increase the risk of bleeding. CSL312, a monoclonal antibody that inhibits the activated blood clotting factor 12 (FXIIa) will be assessed for its potential to prevent thrombus formation in subjects with cancer at risk of PICC-associated thrombosis.
Conditions
- PICC-associated Thrombosis
Interventions
CSL312Drug
CSL312 administered as an IV infusion
PlaceboDrug
Solution of 70% 0.9% saline / 30% CSL312 diluent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with PICC-associated thrombosisTime frame: Up to 29 days after PICC insertion
- Percent of subjects with PICC-associated thrombosisTime frame: Up to 29 days after PICC insertion
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.